Results 101 to 110 of about 107,749 (252)

Fibroblast Plasticity in Inflammation of the Barrier

open access: yesBarrier Immunity, EarlyView.
Under inflammatory condition, fibroblasts in barrier tissues integrate inflammatory, senescent, and mechanical inputs. These pathways activate central signaling networks to drive fibroblast phenotypic transition, enabling cytokine production, immune cell recruitment, and extracellular matrix remodeling.
Chen Zhang, Hao Wu, Wei Li
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang   +7 more
wiley   +1 more source

Advancing therapeutic frontiers: a pipeline of novel drugs for UC management

open access: yesFrontiers in Gastroenterology
Ulcerative colitis is a chronic inflammatory bowel disease with rising global prevalence. Despite therapeutic advances including biologic agents targeting tumor necrosis factor-alpha, integrins, and interleukin pathways, alongside Janus kinase inhibitors
Luisa Bertin   +9 more
doaj   +1 more source

Signalling Pathways Implicated in Obesity Associated Cancers [PDF]

open access: yes, 2014
Grant support: The Scottish Government's Rural and Environment Science and Analytical Services Division. Declaration of interest: The author declares that there is no conflict of interest.Peer reviewedPublisher ...
Drew, Janice E.
core   +1 more source

Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells [PDF]

open access: yes, 2018
Acute inflammation is a complex and tightly regulated homeostatic process that includes leukocyte migration from the vasculature into tissues to eliminate the pathogen/injury, followed by a pro-resolving response promoting tissue repair.
Achuthan   +115 more
core   +1 more source

The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]

open access: yes, 2020
Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M   +6 more
core  

Research progress on the role of inflammatory mediators in the pathogenesis of epilepsy

open access: yesIbrain, Volume 11, Issue 1, Page 44-58, Spring 2025.
In the central nervous system, activated immune cells lead to the overproduction of inflammatory mediators through the corresponding signal pathway. Under the stimulation of inflammatory factors, neuroinflammation ultimately occurs. Overexpression of inflammatory mediators and activated immunocytes plays an important role in the emergence and ...
Yue Yu, Fei‐Ji Sun
wiley   +1 more source

Effectiveness and safety of upadacitinib in refractory pediatric inflammatory bowel disease: A single-arm meta-analysis of observational studies

open access: yesThe Saudi Journal of Gastroenterology
Background: Upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, has been approved for adults with refractory inflammatory bowel disease (IBD).
Ahmed A. Al Sarkhy   +2 more
doaj   +1 more source

The Role of Endothelin‐1 in Autoimmune Diseases: Mechanistic Insights and Therapeutic Targets

open access: yesiNew Medicine, EarlyView.
The Role of Endothelin‐1 in Autoimmune Diseases. NF‐κB: nuclear factor kappa‐B; MAPK: mitogen‐activated protein kinase; PI3K: phosphoinositide 3‐kinase; ROS: reactive oxygen species; CTGF: connective tissue growth factor; TGF‐β: transforming growth factor‐β.
Xun Gong   +5 more
wiley   +1 more source

Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Tofacitinib is a selective Janus kinase (JAK‐1) inhibitor approved for the treatment of ulcerative colitis (UC) in adults. Data is limited in the pediatric population. The aim of this study was to evaluate the efficacy of tofacitinib in pediatric inflammatory bowel disease (IBD).
Denise D. Young   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy